newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology

BIAFBIAFW
  • bioAffinity Technologies announced the allowance of a Mexican patent application for methods predicting lung cancer likelihood using flow cytometry.
  • The patent will protect the use of defined antibodies & the porphyrin TCPP to label cell populations in sputum & the use of flow cytometry to detect lung cancer cells.
  • CyPath Lung is a noninvasive diagnostic test utilizing flow cytometry & artificial intelligence to assess indeterminate pulmonary nodules in high-risk patients.
  • The company's intellectual property portfolio for CyPath Lung now includes patents in the United States, European Union, China, Japan, Australia, Canada & Mexico.
  • Clinical trials demonstrated the test achieved 92% sensitivity, 87% specificity, 88% accuracy & 99% negative predictive value for patients with nodules under 20 millimeters.
  • The test is marketed as a Laboratory Developed Test (LDT) overseen under CLIA regulations & is not intended for use as a sole diagnostic tool.
  • CEO Maria Zannes stated the patent strengthens shareholder value & protects the proprietary approach for early-stage lung cancer detection.